NCT02371031终止1 期
FDOPA-PET/MRI for the Pre-operative Evaluation of Gliomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 11
- 试验地点
- 1
- 主要终点
- Percentage of cases in which the addition of FDOPA-PET to MRI changes the surgical plan
研究概览
简要总结
This is a pilot study designed to evaluate the potential of using FDOPA-PET/MRI for improving surgical planning and providing non-invasive prognostic information in patients with gliomas that have substantial non-enhancing regions. The results will be used to develop larger adequately powered studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Known or suspected diagnosis of intracranial glioma with substantial non-enhancing regions as assessed by contrast enhanced MRI. For the purposes of this study, gliomas with substantial non-enhancing regions are defined as having contrast-enhancing volumes of less than 50% of the total estimated tumor volume. Gliomas that do not have any contrast-enhancing regions are eligible for this study.
- •Standard of care surgical resection and/or stereotactic biopsy of the brain tumor planned within 2 weeks of the FDOPA-PET/MRI study.
- •At least 18 years of age.
- •Measurable disease on MRI defined as tumor measuring at least 1 cm in two perpendicular dimensions.
- •Karnofsky performance of > 50 corresponding to ECOG categories 0, 1, or
- •Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
- •Creatinine clearance or radioisotope glomerular filtration rate (GFR) > 30 mL/min/1.73 m^2
- •Patient or legally authorized representative must be able to understand and willing to sign a written informed consent document.
排除标准
- •Patients undergoing PET/MRI: contraindication to gadolinium contrast enhanced brain MRI (i.e., allergy to gadolinium contrast, MRI-incompatible implantable devices, GFR < 30 mL/min/1.73, and severe claustrophobia). At the discretion of the responsible physician, FDOPA-PET/CT may be performed if PET/MRI is contraindicated or unavailable. If FDOPA-PET/CT is performed, the patient must have undergone a contrast-enhanced MRI for fusion with FDOPA-PET no more than 4 weeks before the FDOPA-PET/CT.
- •Prior chemotherapy or radiation therapy for the brain tumor. Prior biopsy or surgical resection of the glioma without additional therapy is not an exclusion criterion.
- •Pregnant and/or breastfeeding. Women of childbearing potential must have a negative urine or serum pregnancy test no more than 3 days prior to FDOPA injection.
研究组 & 干预措施
Arm 1: FDOPA-PET/MRI
Experimental
- Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.
- In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.
- When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling.
干预措施: 6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine (Drug)
Arm 1: FDOPA-PET/MRI
Experimental
- Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.
- In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.
- When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling.
干预措施: PET/MRI (Device)
Arm 1: FDOPA-PET/MRI
Experimental
- Patients with known or suspected brain gliomas that are non-enhancing or have substantial non-enhancing regions will undergo FDOPA-PET/MRI within 2 weeks prior to planned standard of care surgical resection and/or stereotactic biopsy. In the same planning session, the MRI alone will be reviewed and then the FDOPA-PET data will be added to the planning.
- In the event that a patient cannot undergo MRI or PET/MRI is not available (e.g. due to maintenance), FDOPA-PET/CT can be performed instead at the discretion of the responsible physician.
- When feasible and at the discretion of the neurosurgeon performing the resection, areas of suspected tumor identified on the FDOPA-PET/MRI study but not the MRI alone will undergo tissue sampling.
干预措施: Surgical resection (standard of care) (Procedure)
结局指标
主要结局
Percentage of cases in which the addition of FDOPA-PET to MRI changes the surgical plan
时间窗: At the time of surgery (approximately week 2)
We will consider our primary endpoint successful if FDOPA-PET changes the surgical plan in at least 4 of the 20 patients (20%), a much lower margin than previously reported with \[C-11\]methionine which is on the order of 60-70% of cases. When safe and feasible, these discrepant areas identified on FDOPA-PET/MRI will undergo tissue sampling. However, tissue sampling of discrepant areas may not be possible in all patients, and this decision will be made by the treating neurosurgeon.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
2 期
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital HyperinsulinismCongenital HyperinsulinismNCT04205604Miguel Pampaloni50
Unknown
早期 1 期
PET-CT vs. Integrated MR-PET Scanning of GYN CancersEndometrial CancerOvarian CancerCervical CancerNCT01779128Massachusetts General Hospital100
撤回
不适用
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal CancerClinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Advanced Oropharyngeal Squamous Cell CarcinomaPathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8NCT04140513Ohio State University Comprehensive Cancer Center
已完成
不适用
Effects of Preoperative Physical Therapy in Patients With Lower Extremity MalignancyOsteosarcomaMalignant Peripheral Nerve Sheath SarcomaMalignant Fibrous Histiocytoma of the BoneChondrosarcoma of the BoneSynovial SarcomaRhabdomyosarcomaEwing's SarcomaNCT01674101St. Jude Children's Research Hospital20
已完成
3 期
Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma MetastasesLiver MetastasesColorectal CancerNCT00265356Ontario Clinical Oncology Group (OCOG)404